Business Context and Reporting Period
This Form 8-K, dated February 5, 2026, reports on Becton, Dickinson and Company (BD). The filing discloses a strategic reorganization of the company's business segments effective October 1, 2025, and provides recast historical revenue data to align with the new structure.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. Instead, it references Exhibit 99.1, which contains unaudited historical recast supplemental revenue information for fiscal year 2025 and prior periods. The filing lists several registered debt securities, including notes due in 2026, 2031, 2032, and 2036.
Material Changes
- Segment Reorganization: Effective October 1, 2025, BD reorganized into five worldwide business segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences.
- Life Sciences Divestiture: On July 13, 2025, BD entered a definitive agreement to combine its Biosciences and Diagnostic Solutions businesses with Waters Corporation. Consequently, the Life Sciences segment will be eliminated from future segment reporting, leaving four reportable segments.
- Recast Data: Historical segment revenues for fiscal year 2025 and prior periods have been recast to reflect the new segment structure.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the structural changes noted. It explicitly states that the information in Exhibit 99.1 includes non-GAAP measures and that the report is not deemed "filed" under Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific recast revenue figures by the new business segments.
- Verify the details of the non-GAAP adjustments referenced in the recast schedules.
- Confirm the timeline and closing conditions for the combination of the Life Sciences business with Waters Corporation.
- Assess the impact of the segment elimination on future quarterly reporting and comparability.